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 INTRODUCTION 
 
Ingestion of viable probiotic microorganisms results in various health benefits. Maintaining the viability and assuring targeted delivery of probiotics is 
of great scientific interest, since the production process and the harsh conditions of the gastrointestinal tract often impair the delivery of viable 
microorganisms in the lower intestine. The first barrier to overcome is the acidic stomach environment.  
OBJECTIVES 
 
The objective of this work was to prepare optimal formulation of L. casei loaded whey protein-Ca-alginate microparticles with potential for 
controlled release and colon-targeted delivery of the probiotic. 
RESULTS 
 
Eleven series were prepared and negatively charged microparticles 
were obtained, with size 6.99-9.88 μm after freeze-drying, Ca-
content 0.29-0.47 mg/10 mg and viability of the probiotic 9.30-10.87 
log10cfu/g. The probiotic load in the microparticles after incubation for 
3h in simulated gastric juice containing pepsin was significantly 
higher (6.20-9.77 log10cfu/g) than the viability of the free cells (2.68 
log10cfu/g). (Fig. 1). In addition, the viability of the microencapsulated 
L. casei in simulated colonic condition, pH 7.4, after 24 h was 
8.68±0.15 log10 cfu/g. 
  
CONCLUSIONS 
 
Optimal formulation of L. casei loaded whey protein-Ca-alginate microparticles was prepared with physicochemical and 
biopharmaceutical properties suitable for improving viability of the probiotic cells with anti-inflammatory properties in the GIT and 
providing their controlled release and colon-targeted delivery. 
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Fig. 2 Effect of the experimental 
variables on the survival of L. casei 
loaded in whey protein-Ca-alginate 
microparticles: after freeze-drying (a), 
after 3 h in SGJ (b). 
Fig. 1 Viability of the microencapsulated L. casei (log10cfu/g) in 
simulated gastric juice 
  
The regression coefficients showed that the viability of the probiotic is 
dominantly (positively) affected by the concentration of whey proteins, 
followed by the influence of calcium. (Fig. 2). This confirms the 
protective role of the additional coating of whey proteins, which are not 
completely degradable in gastric juice and provide the desirable 
targeted delivery in the large intestine/colon. 
The anti-inflammatory properties were confirmed by the significant 
decrease (p<0.05) in the level of myeloperoxidase in Wistar rats, in 
which TNBS colitis was induced (Fig. 3). These results were confirmed 
by clinical score and microscopic examination of the transversal 
section of the extracted colonic tissue (Fig. 4, 5).  
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Fig. 3  Myeloperoxidase activity in  examined  rat groups 
Fig. 4 Transversal section of colonic tissue:  
control group (a), colitic group (b) 
Fig. 5 Transversal  section of colonic tissue: 
group treated with free L.casei (a) and group 
treated with encapsulated L.casei (b) 
METHODS 
 
Emulsion technique was applied to aqueous dispersion of alginate 
and L. casei in olive oil, to obtain spherical particles, which were then 
cross-linked in CaCl2 solution. Microparticles were subsequently 
coated with native 100% hydrolyzed whey protein isolate, collected, 
washed and freeze- dried (-50ºC, 0.070 mbar, 24 h). 
To deduce the influence of formulation variables, polynomial 
regression model at 2nd level was used with the experimental matrix of 
11 series, and concentration limits of three variables alginate (1 and 
4%m/m), whey protein (1 and 3%m/m) and CaCl2 (1 and 5%m/m). 
The cell load in the initial suspension was ca. 10-11 log10cfu/g. 
The viability of microencapsulated L. casei was examined in simulated 
gastric juice (SGJ) (0.08M HCl with 0.2% NaCl and 3g/l pepsin, pH 
1.5) for 3 h, simulated intestinal juice (0.05 mol/L KH2PO4, pH 6.8) 
with 1% (w/v) bile salts and 10 g/L pancreatin  for additional 3 h and in 
simulated colon medium (0.1 mol/L KH2PO4; pH 7.4) up to 24 h. 
The anti-anflammatory properties of the probiotic were assessed by 
oral administration of the optimal formulation of microparticles once 
daily (probiotic viability 8,7 log10cfu/g) during 21 days to Wistar rats in 
which inflammation by intrarectal administration of TNBS in ethanol 
was induced (10 mg in 0.25 ml 50% ethanol). Clinical score and 
activity of myeloperoxidase in the colonic tissue were determined after 
12 days in comparison with the positive and negative control group 
and group of rats treated with non-encapsulated probiotic cells. 
